Beta-blockade intolerance in anthracycline-induced cardiomyopathy.
Beta-blockade efficiency and safety in anthracycline induced cardiomyopathy (AIC) are poorly documented. Cardiac Heart Failure (CHF) due to an AIC has haemodynamic and histologic particularities: only mild ventricular dilatation, restriction pattern and myocardial and endocardial fibrous thickening. Therefore, beta blockade therapy initiation may cause heart failure decompensation by absence of the usual left ventricular adaptation (improvement of left ventricular compliance allowing maintenance of stroke volume). We describe an AIC patient in whom a first beta-blockade initial administration caused a global cardiac failure; after stabilisation, one month later, a second attempt caused a new cardiac failure. We raise the question of beta-blockade safety in restrictive cardiomyopathies.
Jean-Yves
JY
Tabet
Philippe
P
Meurin
Ahmed
A
Ben Driss
Xavier
X
Berthaux
Hélène
H
Weber
Nathalie
N
Renaud
Alain
A
Cohen Solal
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018943:Anthracyclines / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D014463:Ultrasonography
D000319:Adrenergic beta-Antagonists; D018943:Anthracyclines